Skip to main content
Premium Trial:

Request an Annual Quote

TheraCode to Acquire JPT Peptide Technologies

NEW YORK (GenomeWeb News) - German-based TheraCode, a wholly owned subsidiary of biotech firm BioNTech, has announced its intentions to buy JPT Peptide Technologies, also based in Germany, for €5 million ($6.8 million) in an all-cash deal.

JPT had been a wholly owned subsidiary of Jerini, which sold the company as part of its strategy to divest non-strategic businesses and focus on its core business, the commercialization of the drug icatibant (Firazyr) for the treatment of hereditary angioedema.

JPT provides peptide-based services as well as high-content peptide arrays, peptide tools, and peptide libraries "for all development phases of novel vaccines," TheraCode said in an announcement, adding that the purchase will enable JPT to accelerate expansion of its services.

"The investment in JPT not only provides us with access to its unique and proprietary portfolio of peptide technologies," said Ugur Sahin, CEO of BioNTech, "it will also accelerate JPT's continued growth, increase its visibility, and further improve its well-recognized services to an international client base."

For TheraCode, the acquisition is part of its long-term strategy to provide "comprehensive technology platforms for drug and biomarker development," said Sahin.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.